ÍøºìºÚÁÏ

Skip to main content

Christopher R Cogle, MD : Research

Cancer Specialist (Oncologist)

Photo of Christopher R Cogle

Research at a glance

Top areas of exploration

  • Leukemia, Myeloid, Acute , 24 publications
  • Myelodysplastic Syndromes , 24 publications
  • Hematopoietic Stem Cell Transplantation , 20 publications
  • Bone Marrow Cells , 15 publications

Research activity

172 publications

6,035 citations

Why is this important?

Focus

Christopher R. Cogle, M.D. is a physician and scientist with research focus on cancer and health policy. In his early career Dr. Cogle discovered that blood stem cells make blood vessels and used that biology to invent new therapeutics and diagnostics for people with cancer and heart disease. In his mid career, as a Leukemia & Lymphoma Society Scholar in Clinical Research, he translated laboratory research discoveries into investigator-initiated clinical trials. Dr. Cogle has also made major discoveries in cancer epidemiology and was elected to lead Florida’s cancer prevention and control efforts at the state level, producing the Florida Cancer Plan, leading statewide campaigns for improved cancer prevention and control, and advising the Florida Legislature, Florida Secretary of ÍøºìºÚÁÏ, and Florida Governor on evidence-based strategies to reduce the state's cancer burden. In 2020, Dr. Cogle was selected by the National Academy of Medicine as an Emerging Leader in ÍøºìºÚÁÏ and Medicine Scholar. In 2021, Dr.Cogle founded the Florida ÍøºìºÚÁÏ Policy Leadership Academy at the Bob Graham Center for Public Service. His academy team of faculty trains Florida's community leaders in promoting health and preventing disease and disease progression for Florida's 21 million residents and 100 million visitors. In 2023, he was selected by the Milbank Memorial Foundation as a state health policy fellow.

My publications

172 publications

2021

Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA.

Frontiers in oncology

•

2021

Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.

International journal of laboratory hematology

•

2021

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

Cancers

•

2021

Vaccine Enthusiasm and Hesitancy in Cancer Patients and the Impact of a Webinar

ÍøºìºÚÁÏcare

•

2020

Cancer in the Time of Coronavirus: A Call for Crisis Oncology Standards of Care

ÍøºìºÚÁÏcare

•